The past year has been a time of significant growth for Seagen, but one thing has always remained the same: our passion for delivering innovative therapies to people impacted by #cancer. Learn about the meaningful work we’re doing at Seagen and how you can contribute to that mission.
Breaking News: Seattle Genetics announces FDA filing acceptance for priority review of Tucatinib.
We’re proud to announce alongside our partner Astellas Pharma US, the U.S. FDA approval of the first antibody-drug conjugate for the treatment of adults with locally advanced or metastatic bladder cancer and other urothelial cancers. Thank you to the patients and families who participated the clinical trial leading to this approval, and to the doctors who led the research resulting in this new medicine for patients. http://glassdoor.com/slink.htm?key=vMghF
We are excited to announce positive topline results from a pivotal clinical trial evaluating our investigational agent in patients with metastatic HER2-positive breast cancer. Read more here: http://glassdoor.com/slink.htm?key=vMRle
We are enthused to announce, alongside our partner Astellas, that the U.S. FDA accepted the Biologics License Application granting Priority Review for our investigational agent in advanced or metastatic urothelial cancer. We’re proud to advance bladder cancer research for patients. http://glassdoor.com/slink.htm?key=vMc3O
Thanks to our 2019 summer interns and good luck as you head back to class!
We are pleased to announce, along with our partner Astellas Pharma US, submission of a Biologics License Application (BLA) to the U.S. FDA for an investigational agent to treat advanced or metastatic #urothelial cancer #bladdercancer http://glassdoor.com/slink.htm?key=vMiak
We're excited to announce the appointment of Robin Taylor, Ph.D., as Chief Commercial Officer http://glassdoor.com/slink.htm?key=vMEUX
We presented positive phase 3 ALCANZA clinical trial data for cutaneous T-cell #lymphoma w/ @TakedaOncology at #ASH16 http://glassdoor.com/slink.htm?key=vQA9o
We’re excited to be at #ASH16 to discuss new research in #Hodgkin #lymphoma, as part of 18 abstracts & 8 oral presentations. http://glassdoor.com/slink.htm?key=vQA9Z